vs
Side-by-side financial comparison of H2O AMERICA (HTO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
H2O AMERICA is the larger business by last-quarter revenue ($199.4M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). H2O AMERICA runs the higher net margin — 8.1% vs 1.6%, a 6.5% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 1.5%). Over the past eight quarters, H2O AMERICA's revenue compounded faster (15.3% CAGR vs -0.2%).
H2O Wireless is a United States-based prepaid cell phone service, that utilizes the AT&T network. It is a brand of the mobile virtual network operator (MVNO) Locus Telecommunications, a subsidiary of Telrite Holdings, Inc., since 2019. Locus was formerly a subsidiary of KDDI America corporation, starting in 2010. H2O Wireless is primarily advertised as a non-restrictive phone service for customers to bring or buy unlocked smartphones, although AT&T contract/locked phones may be accepted as well.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HTO vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $199.4M | $177.4M |
| Net Profit | $16.2M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 16.6% | 3.9% |
| Net Margin | 8.1% | 1.6% |
| Revenue YoY | 1.5% | 5.0% |
| Net Profit YoY | -29.2% | — |
| EPS (diluted) | $0.45 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $199.4M | $196.9M | ||
| Q3 25 | $243.5M | $179.5M | ||
| Q2 25 | $197.8M | $181.1M | ||
| Q1 25 | $164.9M | $168.9M | ||
| Q4 24 | $196.5M | $187.3M | ||
| Q3 24 | $216.7M | $168.6M | ||
| Q2 24 | $173.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $16.2M | — | ||
| Q3 25 | $45.1M | $5.4M | ||
| Q2 25 | $24.7M | $-4.8M | ||
| Q1 25 | $16.6M | $4.8M | ||
| Q4 24 | $22.9M | — | ||
| Q3 24 | $38.7M | $-143.5M | ||
| Q2 24 | $20.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 16.6% | 1.2% | ||
| Q3 25 | 26.5% | 3.5% | ||
| Q2 25 | 22.2% | 4.7% | ||
| Q1 25 | 21.8% | 1.2% | ||
| Q4 24 | 22.2% | 13.2% | ||
| Q3 24 | 26.9% | -82.8% | ||
| Q2 24 | 23.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 8.1% | — | ||
| Q3 25 | 18.5% | 3.0% | ||
| Q2 25 | 12.5% | -2.7% | ||
| Q1 25 | 10.0% | 2.8% | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 17.8% | -85.1% | ||
| Q2 24 | 12.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.45 | $0.05 | ||
| Q3 25 | $1.27 | $0.12 | ||
| Q2 25 | $0.71 | $-0.11 | ||
| Q1 25 | $0.49 | $0.10 | ||
| Q4 24 | $0.70 | $0.38 | ||
| Q3 24 | $1.17 | $-3.11 | ||
| Q2 24 | $0.64 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.7M | $144.3M |
| Total DebtLower is stronger | $1.9B | — |
| Stockholders' EquityBook value | $1.5B | $653.9M |
| Total Assets | $5.1B | $1.2B |
| Debt / EquityLower = less leverage | 1.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $20.7M | $238.4M | ||
| Q3 25 | $11.3M | $246.3M | ||
| Q2 25 | $19.8M | $445.9M | ||
| Q1 25 | $23.7M | $493.6M | ||
| Q4 24 | $11.1M | $484.6M | ||
| Q3 24 | $4.0M | $453.8M | ||
| Q2 24 | $22.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.9B | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $1.7B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.5B | $693.1M | ||
| Q3 25 | $1.5B | $727.2M | ||
| Q2 25 | $1.5B | $757.8M | ||
| Q1 25 | $1.4B | $798.5M | ||
| Q4 24 | $1.4B | $778.3M | ||
| Q3 24 | $1.3B | $749.6M | ||
| Q2 24 | $1.3B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $5.1B | $1.3B | ||
| Q3 25 | $5.0B | $1.3B | ||
| Q2 25 | $4.8B | $1.5B | ||
| Q1 25 | $4.7B | $1.6B | ||
| Q4 24 | $4.7B | $1.6B | ||
| Q3 24 | $4.6B | $1.5B | ||
| Q2 24 | $4.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.23× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 1.26× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.5M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.92× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $63.5M | $43.7M | ||
| Q3 25 | $77.3M | $60.8M | ||
| Q2 25 | $60.8M | $12.0M | ||
| Q1 25 | $43.2M | $35.5M | ||
| Q4 24 | $41.5M | $33.1M | ||
| Q3 24 | $53.5M | $53.9M | ||
| Q2 24 | $49.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.92× | — | ||
| Q3 25 | 1.71× | 11.20× | ||
| Q2 25 | 2.47× | — | ||
| Q1 25 | 2.61× | 7.37× | ||
| Q4 24 | 1.81× | — | ||
| Q3 24 | 1.39× | — | ||
| Q2 24 | 2.38× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTO
| Water Utility Services | $191.0M | 96% |
| Other | $8.4M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
